Black Diamond Therapeutics
BDTX
73 hedge funds and large institutions have $107M invested in Black Diamond Therapeutics in 2023 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 23 increasing their positions, 15 reducing their positions, and 17 closing their positions.
866% more call options, than puts
Call options by funds: $1.05M | Put options by funds: $109K
53% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 15
0% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 17
1% less funds holding
Funds holding: 74 → 73 (-1)
8.2% less ownership
Funds ownership: 80.31% → 72.11% (-8.2%)
49% less capital invested
Capital invested by funds: $209M → $107M (-$102M)
100% less funds holding in top 10
Funds holding in top 10: 2 → 0 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
+$7.93M |
| 2 |
Verition Fund Management
Greenwich,
Connecticut
|
+$4.73M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.78M |
| 4 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.47M |
| 5 |
Barclays
London,
United Kingdom
|
+$729K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$8.59M |
| 2 |
BC
Boxer Capital
San Diego,
California
|
-$5.56M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$4.41M |
| 4 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$3.79M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.26M |
BDTX Hedge Fund Activity: Q3 2023 in Review
73 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q3 2023, worth a combined $107M — down 49% from $209M a quarter earlier.
Fund positioning in BDTX was balanced in Q3 2023: 17 funds opened new positions, 17 closed out, 23 added to existing stakes and 15 trimmed.
The largest buyer was T. Rowe Price Investment Management, opening a new position worth an estimated $7.93M. The largest seller was RTW Investments, exiting entirely with an estimated $8.59M sold.
- 73 institutional investors held Black Diamond Therapeutics (BDTX) as of Q3 2023, down from 74 in Q2 2023.
- Funds reported $107M of Black Diamond Therapeutics stock for Q3 2023, down 49% quarter-over-quarter.
- 17 funds opened new Black Diamond Therapeutics positions in Q3 2023 and 17 closed out, a net change of 0 holders.
- The largest Black Diamond Therapeutics buyer in Q3 2023 was T. Rowe Price Investment Management, an estimated $7.93M added.
- The largest Black Diamond Therapeutics seller in Q3 2023 was RTW Investments, an estimated $8.59M sold.
Based on aggregated 13F filings for Q3 2023.